Automation in Australian Pharma & Biotech: Strategic Partnerships Powering the Next Leap
Discover how automation is transforming Australia’s pharmaceutical and biotechnology manufacturing. From GMP compliance to real-world innovation with partners like Bürkert, see how leading manufacturers are streamlining processes, boosting quality, and future-proofing their operations.
Australia’s pharmaceutical and biotechnology manufacturing sectors are entering a new era, one defined by the need for regulatory compliance, efficiency, and data-driven production.1 As the industry faces mounting pressure to accelerate innovation, reduce costs, and ensure the highest standards of quality, strategic partnerships with automation specialists like Burkert are proving to be a catalyst for transformation.
Local Industry Needs, Global Automation Expertise
Australian manufacturers operate in a landscape marked by strict GMP requirements2, high labour costs, and growing demand for personalised medicine. Automation is no longer just an option, it’s essential for maintaining competitiveness and compliance. But not all automation solutions are created equal. The difference lies in partnering with companies that bring both global innovation and local expertise.
Burkert, a global leader in fluid control and automation, has established itself as a trusted partner to Australia’s pharma and biotech sectors. Their comprehensive portfolio includes modular valve systems, control cabinets, and digital process solutions designed specifically for the unique demands of pharmaceutical production, from fermenters and bioreactors, to WFI (Water for Injection) and clean utility systems.
Case Study: AstraZeneca and Burkert—A Model for Strategic Partnership
A standout example of Burkert’s impact in Australia is their partnership with AstraZeneca’s North Ryde manufacturing plant in Sydney. Tasked with expanding and modernising facilities for respiratory medication production, AstraZeneca needed a solution that would fully automate processes, improve data availability, and meet the world’s most rigorous pharmaceutical standards.
Burkert delivered a decentralised control solution using intelligent automated valve control heads with fieldbus communication. This approach minimised wiring and installation costs, reduced commissioning time, and provided operators with clear, real-time status indication. Notably, Burkert’s engineering team developed a bespoke LED status system to match AstraZeneca’s SCADA colour coding, demonstrating their commitment to true partnership and customisation.
Beyond Components: Co-Engineering for Operational Excellence
Burkert’s value extends far beyond supplying components. Their approach is collaborative, supporting partners from initial design through to commissioning and ongoing optimisation. Whether it’s developing custom valve blocks, integrating digital process monitoring, or ensuring compatibility with plant-wide automation systems, Burkert empowers Australian pharma and biotech manufacturers to future-proof their operations.
By choosing Burkert as a strategic automation partner, Australian manufacturers gain access to global best practices, local engineering support, and solutions tailored for the most demanding GMP environments. The result? Safer, more efficient, and highly compliant pharmaceutical and biotechnology production, delivered through partnership.
1 McKinsey & Company. (2025, May 8). Human–machine harmonization to upgrade biopharma production. https://www.mckinsey.com/capabilities/operations/our-insights/human-machine-harmonization-to-upgrade-biopharma-production
2 BioProcess International. (n.d.). Robots in biomanufacturing: A road map for automation of biopharmaceutical operations. https://www.bioprocessintl.com/information-technology/robots-in-biomanufacturing-a-road-map-for-automation-of-biopharmaceutical-operations